Teva Pharmaceutical Industries Limited Company Profile (NYSE:TEVA)

Teva Pharmaceutical Industries Limited trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries Limited declared a quarterly dividend on Monday, August 7th. Investors of record on Tuesday, August 29th will be paid a dividend of $0.085 per share on Thursday, September 14th. This represents a $0.34 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date of this dividend is Friday, August 25th. View Teva Pharmaceutical Industries Limited's Dividend History.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) posted its quarterly earnings results on Thursday, August, 3rd. The company reported $0.99 EPS for the quarter, missing analysts' consensus estimates of $1.06 by $0.07. The company earned $5.69 billion during the quarter, compared to analysts' expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business's quarterly revenue was up 12.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.25 earnings per share. View Teva Pharmaceutical Industries Limited's Earnings History.

Teva Pharmaceutical Industries Limited is scheduled to release their next quarterly earnings announcement on Tuesday, November, 21st 2017. View Earnings Estimates for Teva Pharmaceutical Industries Limited.

Teva Pharmaceutical Industries Limited updated its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of $4.30-4.50 for the period, compared to the Thomson Reuters consensus estimate of $4.73. The company issued revenue guidance of $22.8-23.2 billion, compared to the consensus revenue estimate of $23.43 billion.

25 brokerages have issued 12 month price objectives for Teva Pharmaceutical Industries Limited's shares. Their forecasts range from $19.00 to $80.00. On average, they anticipate Teva Pharmaceutical Industries Limited's stock price to reach $36.82 in the next year. View Analyst Ratings for Teva Pharmaceutical Industries Limited.

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries Limited stock:

• 1. According to Zacks Investment Research, "Teva missed estimates for both earnings and sales in Q2. The company also slashed its 2017 earnings and sales outlook to reflect the challenging environment in the U.S. generics business and the continued deterioration in Venezuela. Teva also announced a 75% cut in its dividend. The U.S. generics industry’s competitive and pricing pressure is expected to continue in the near future. Teva is facing several other challenges in the form of generic competition for Copaxone, new competition for branded products, a high cost base and debt load and the sudden departure of its CEO. Also, Teva’s shares underperformed the generic industry this year so far. Nonetheless, Teva is progressing with its branded/generics drugs pipeline and is looking to strengthen its biosimilar pipeline. The Actavis Generics acquisition is contributing to the growth of the Generics unit. However, a clear path to growth is not visible." (8/9/2017)
• 2. Jefferies Group LLC analysts commented, "MDCO announced early stoppage of the Ph 3 TANGO-2 trial for Vabomere (Carbavance) based on an interim analysis which showed a superior benefit-risk compared to best available therapy in serious infections due to CRE. We are impressed by DSMB stoppage of a trial with less than half of patients enrolled (72 out of the 150 target) suggesting a dramatic clinical benefit vs. standard of care. We believe today’s news provides a favorable setup for the August 21 (our estimate) PDUFA for Vabomere in cUTI. We continue to see Vabomere as a potential source of optionality for MDCO should management decide to launch this important new antibiotic on their own or in conjunction with a partner." (7/25/2017)
• 3. Maxim Group analysts commented, "We reviewed and revised our model prior to the 1Q17 earnings release. Based on 2017 guidance and our expectations, we adjust OTC revenues in 1Q17 to $277M from $346M to reflect the change in foreign exchange rate as of December 1, 2016. Our estimate for total 2017 revenues is unchanged at $24B." (3/29/2017)
• 4. Royal Bank Of Canada analysts commented, "TEVA reported 4Q above Street expectations and reaffirmed 2017 guidance with some further color around the year. The bull case in TEVA lacks conviction and change is needed. We look to CEO search/ strategic review, potential for break-up, and potential upside from generic Copaxone surprise as opportunity but near-term confidence remains low. No change to PT but EPS moves lower to reflect greater competitive pressures." (2/14/2017)

Teva Pharmaceutical Industries Limited saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 45,907,938 shares, an increase of 16.9% from the July 14th total of 39,285,360 shares. Based on an average daily trading volume, of 4,970,113 shares, the short-interest ratio is presently 9.2 days.

Some companies that are related to Teva Pharmaceutical Industries Limited include Shire PLC (SHP), Dr. Reddy's Laboratories Ltd (RDY), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Taro Pharmaceutical Industries (TARO), Akorn (AKRX), Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Horizon Pharma PLC (HZNP), Amicus Therapeutics (FOLD), Cambrex Corporation (CBM), Corcept Therapeutics Incorporated (CORT), Theravance Biopharma (TBPH), Pacira Pharmaceuticals (PCRX), Emergent Biosolutions (EBS) and Innoviva (INVA).

Teva Pharmaceutical Industries Limited's management team includes the folowing people:

• Sol J. Barer, Chairman of the Board
• Yitzhak Peterburg, Interim President and Chief Executive Officer
• Eyal Desheh, Group Executive Vice President, Chief Financial Officer
• Dipankar Bhattacharjee, President and Chief Executive Officer-Global Generic Medicines Group
• Carlo de Notaristefani, President and Chief Executive Officer-Global Operations
• Robert Koremans, President, Chief Executive Officer - Global Specialty Medicines
• Iris Beck-Codner, Group Executive Vice President - Corporate Marketing & Communication
• Hafrun Fridriksdottir, Executive Vice President, President of Global Generics R&D
• Mark Sabag, Group Executive Vice President-Human Resources
• David M. Stark, Group Executive Vice President-Chief Legal Officer

Teva Pharmaceutical Industries Limited's stock is owned by many different of institutional and retail investors. Top institutional investors include Capital Research Global Investors (7.51%), Franklin Resources Inc. (6.57%), FMR LLC (4.22%), Bank of New York Mellon Corp (1.79%), Northern Cross LLC (1.75%) and Nordea Investment Management AB (1.27%). View Institutional Ownership Trends for Teva Pharmaceutical Industries Limited.

Teva Pharmaceutical Industries Limited's stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, FIL Ltd, Janus Henderson Group PLC, South Texas Money Management Ltd., Great West Life Assurance Co. Can, Banque Pictet & Cie SA, Commerzbank Aktiengesellschaft FI and Airain ltd. View Insider Buying and Selling for Teva Pharmaceutical Industries Limited.

Teva Pharmaceutical Industries Limited's stock was bought by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Franklin Resources Inc., FMR LLC, Capital World Investors, Alliancebernstein L.P., Migdal Insurance & Financial Holdings Ltd., Northern Cross LLC and Polaris Capital Management LLC. View Insider Buying and Selling for Teva Pharmaceutical Industries Limited.

Shares of Teva Pharmaceutical Industries Limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Teva Pharmaceutical Industries Limited stock can currently be purchased for approximately $17.30.